Vigil likely to land Alzheimer’s deal after today’s data, says Mizuho

Mizuho analyst Graig Suvannavejh says Vigil Neuroscience (VIGL) this morning reported positive top-line P1 data for VG-3927, a novel small molecule TREM2 agonist for Alzheimer’s disease. The firm is “pleased to see” VG-3927 show a “very safe and well-tolerated profile, with excellent” pharmacokinetic-pharmacodynamic properties, and “robust” target engagement. Mizuho believes the likelihood that Vigil lands a “large” Alzheimer’s partnership deal for VG-3927 before the Phase 2 study start is “quite high.” It reiterates an Outperform rating on the shares with a $13 price target Vigil Neuroscience in morning trading is up 9% to $2.22.